AU2012317424B2 - Crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate - Google Patents

Crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate Download PDF

Info

Publication number
AU2012317424B2
AU2012317424B2 AU2012317424A AU2012317424A AU2012317424B2 AU 2012317424 B2 AU2012317424 B2 AU 2012317424B2 AU 2012317424 A AU2012317424 A AU 2012317424A AU 2012317424 A AU2012317424 A AU 2012317424A AU 2012317424 B2 AU2012317424 B2 AU 2012317424B2
Authority
AU
Australia
Prior art keywords
hydroxy
crystal
carboxamide
imidazole
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012317424A
Other languages
English (en)
Other versions
AU2012317424A1 (en
AU2012317424A8 (en
Inventor
Taisuke Fujimoto
Tomohiro Hashimoto
Katsuyuki Hayashi
Tomoyuki Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of AU2012317424A1 publication Critical patent/AU2012317424A1/en
Publication of AU2012317424A8 publication Critical patent/AU2012317424A8/en
Application granted granted Critical
Publication of AU2012317424B2 publication Critical patent/AU2012317424B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2012317424A 2011-09-28 2012-09-28 Crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate Ceased AU2012317424B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-213500 2011-09-28
JP2011213500 2011-09-28
JP2011-213501 2011-09-28
JP2011213501 2011-09-28
PCT/JP2012/075106 WO2013047758A1 (ja) 2011-09-28 2012-09-28 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド水和物の結晶及び５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の結晶及びその製造方法

Publications (3)

Publication Number Publication Date
AU2012317424A1 AU2012317424A1 (en) 2014-04-17
AU2012317424A8 AU2012317424A8 (en) 2014-07-03
AU2012317424B2 true AU2012317424B2 (en) 2017-05-18

Family

ID=47995783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012317424A Ceased AU2012317424B2 (en) 2011-09-28 2012-09-28 Crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate

Country Status (13)

Country Link
US (2) US9108928B2 (enExample)
EP (1) EP2762469B1 (enExample)
KR (1) KR101970509B1 (enExample)
CN (1) CN103827093B (enExample)
AU (1) AU2012317424B2 (enExample)
BR (1) BR112014007436A2 (enExample)
CA (1) CA2850196A1 (enExample)
IL (2) IL231677A (enExample)
IN (1) IN2014CN02346A (enExample)
MX (1) MX354498B (enExample)
RU (2) RU2672560C1 (enExample)
SG (1) SG11201400974VA (enExample)
WO (1) WO2013047758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN02346A (enExample) 2011-09-28 2015-06-19 Fujifilm Corp
JP6001684B2 (ja) * 2013-01-15 2016-10-05 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミドの硫酸塩
WO2015105174A1 (ja) 2014-01-10 2015-07-16 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドの有効投与量または感受性の予測方法および予測装置、キサントシン一リン酸の量の測定方法ならびに骨髄異形成症候群の処置剤および処置方法
EP3513791B1 (en) * 2016-09-13 2021-07-28 FUJIFILM Corporation Medicinal drug, method, use, and compound for preventing or curing leukemia associated with mll
WO2019082898A1 (ja) 2017-10-27 2019-05-02 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035168A1 (ja) * 2007-09-14 2009-03-19 Mbr Co., Ltd. ４－カルバモイル－５－ヒドロキシ－イミダゾール誘導体のスルホン酸塩化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
JPS5625165A (en) * 1979-08-08 1981-03-10 Sumitomo Chem Co Ltd Novel imidazole derivative
JPS5824569A (ja) * 1981-08-05 1983-02-14 Sumitomo Chem Co Ltd イミダゾ−ル誘導体の精製方法
US4503235A (en) * 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
JPS60185727A (ja) * 1984-03-05 1985-09-21 Sumitomo Chem Co Ltd ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法
US5567816A (en) 1994-07-26 1996-10-22 Syntex (U.S.A.) Inc. Preparation of acyclovir using 1,3 dioxolane
CA2152863A1 (en) 1994-07-26 1996-01-27 Yeun-Kwei Han Preparation of acyclovir
US7002023B2 (en) 2000-09-29 2006-02-21 Basf Aktiengesellschaft Method for producing 1 substituted 5-chloro-4 methly pyrazoles
JP2002265601A (ja) 2001-03-07 2002-09-18 Rikogaku Shinkokai イミド樹脂
BRPI0607439A2 (pt) * 2005-02-16 2010-04-06 Solvay Pharm Bv compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto
CN101395141A (zh) * 2006-02-24 2009-03-25 莱西肯医药有限公司 咪唑基化合物，包含其的组合物和它们的使用方法
KR100982720B1 (ko) * 2008-02-04 2010-09-17 주식회사 파마코스텍 4-카르바모일-1-β-Ｄ-리보푸라노실이미다졸륨-5-올레이트의 생산을 위한 중간체로서의 2-아미노말론아미드의제조방법
IN2014CN02346A (enExample) 2011-09-28 2015-06-19 Fujifilm Corp
JP5726830B2 (ja) 2011-09-28 2015-06-03 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の結晶及びその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035168A1 (ja) * 2007-09-14 2009-03-19 Mbr Co., Ltd. ４－カルバモイル－５－ヒドロキシ－イミダゾール誘導体のスルホン酸塩化合物

Also Published As

Publication number Publication date
KR20140069052A (ko) 2014-06-09
KR101970509B1 (ko) 2019-04-19
SG11201400974VA (en) 2014-09-26
AU2012317424A1 (en) 2014-04-17
EP2762469A4 (en) 2015-01-14
US9108928B2 (en) 2015-08-18
BR112014007436A2 (pt) 2017-04-04
HK1197406A1 (zh) 2015-01-16
NZ622928A (en) 2015-04-24
IN2014CN02346A (enExample) 2015-06-19
CN103827093A (zh) 2014-05-28
MX354498B (es) 2018-03-08
IL231677A (en) 2017-01-31
IL246754A (en) 2017-08-31
RU2630682C2 (ru) 2017-09-12
EP2762469A1 (en) 2014-08-06
EP2762469B1 (en) 2016-11-23
CN103827093B (zh) 2016-06-15
IL231677A0 (en) 2014-05-28
CA2850196A1 (en) 2013-04-04
US9567303B2 (en) 2017-02-14
US20150315156A1 (en) 2015-11-05
AU2012317424A8 (en) 2014-07-03
RU2672560C1 (ru) 2018-11-16
US20140275568A1 (en) 2014-09-18
RU2014111810A (ru) 2015-11-10
MX2014003638A (es) 2014-05-21
WO2013047758A1 (ja) 2013-04-04

Similar Documents

Publication Publication Date Title
AU2012244791B2 (en) Preparation of high-purity gadobutrol
EP2753616A1 (en) Crystalline forms of afatinib di-maleate
EP2791141B1 (en) Tofacitinib mono-tartrate salt
US11332467B2 (en) Solid state forms of palbociclib dimesylate
US9567303B2 (en) Crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate and pharmaceutical composition thereof
JP2023544775A (ja) ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンのアトロプ異性体をラセミ化及び単離するためのプロセス
KR101785186B1 (ko) 프라수그렐 염의 결정형
KR101333620B1 (ko) 모르피난 유도체의 결정 및 그 제조법
JP5905614B2 (ja) ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の製造方法及びその結晶の製造方法
CZ2014708A3 (cs) Soli Bedaquilinu
NZ622928B2 (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide·3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1 h-imidazole-4-carboxamide hydrate
WO2022250620A1 (en) An improved process for highly pure benserazide hydrochloride and novel anhydrous polymorph thereof
CN114401957B (zh) 一种喹唑啉衍生物的制备方法及其结晶
AU2013368947A1 (en) Process for preparing amorphous Cabazitaxel
HK1197406B (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same
WO2019082898A1 (ja) ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法
CZ2015391A3 (cs) Sůl bedaquilinu s kyselinou citronovou
HK1210080A1 (en) Sulfate of 5-hydroxy-1h-imidazole-4-carboxamide

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 15 , PAGE(S) 2048 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME FUJIFILM CORPORATION, APPLICATION NO. 2012317424, UNDER INID (72) CORRECT THE CO-INVENTOR TO FUJIMOTO, TAISUKE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired